What Borgal Treats: Main Uses and Benefits

Borgal is generally used for managing a wide range of acute and severe bacterial infections, where short-term symptomatic assistance is needed. This medication is commonly applied across multiple therapeutic domains where heightened systemic or localized distress is present, contributing to easing the overall symptom load during difficult episodes.

---

Key Therapeutic Applications

The medication is relevant for addressing conditions presenting with systemic or localized discomfort, including bacterial pneumonias, Bovine Pneumonic Pasteurellosis (shipping fever), enteric issues like colibacillosis and salmonellosis, reproductive disorders such as Mastitis-Metritis-Agalactia (MMA) syndrome in sows, and infections causing lameness like infectious pododermatitis (foot rot). This medication is applied in addressing conditions marked by increased physiological stress.

It is often used during phases when symptoms become more noticeable, such as severe fever, lethargy, and acute diarrhea (scours). This supportive relief may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Acute Distress

Quick Fact: Relief for Acute Distress

Borgal may assist with maintaining functional stability in conditions marked by increased physiological stress, thus contributing to improved comfort during periods of heightened systemic symptoms and functional strain caused by localized infections.

Regulatory References

1. HPRA Product Information

Eligibility Map: Who Can and Cannot Use Borgal

Regulatory agencies define the population eligibility for Borgal (Sulfadoxine/Trimethoprim) based on the animal's physiological state, pre-existing conditions, and concurrent treatments. The product is approved for use in Cattle, Pigs, and Horses.

Population Status	Official Regulatory Classification
Contraindicated Populations	Animals with known sulfonamide hypersensitivity. Animals with severe liver or kidney parenchymal damage. Animals with blood dyscrasias. Pregnant animals (prohibited due to excipient content).
Target Species Allowed	Cattle, Pigs, and Horses (as defined target species).

---

Eligibility-Related Restrictions

Use of Borgal is subject to the following official limitations:

• Concurrent Medication: The intravenous administration route is contraindicated if the animal is simultaneously receiving CNS depressants or alpha 2 agonists due to drug interaction risks.
• Reproductive Status: Safety is not established for use in lactating animals or animals intended for breeding. Use in these groups is strictly conditional upon a detailed veterinary benefit-risk assessment.
• Metabolic State: The medicine is restricted in animals with reduced water intake to mitigate the risk of crystalluria. Furthermore, official regulations may prohibit its use in certain specific populations, such as horses intended for human consumption.

Interactions with other medicines and products

This medicinal product's interaction profile is characterized by documented pharmacokinetic and pharmacodynamic constraints based on its active ingredients, Sulfadoxine and Trimethoprim.

Restrictions and Pharmacokinetic Interactions The combination is formally contraindicated with Dofetilide, as the medicine's ingredients increase Dofetilide plasma exposure by inhibiting the renal organic cation transporter 2 (OCT2). This same transporter-mediated mechanism can increase the plasma concentrations of other OCT2 substrates, including Procainamide and Amantadine.

The product also acts as an inhibitor of certain metabolic enzymes, leading to increased plasma exposure of other medicines. Co-administration may prolong the half-life of Phenytoin and potentiate the effects of oral anticoagulants like Warfarin. Increased serum levels of Digoxin are also a documented outcome, particularly in elderly patients.

Pharmacodynamic Effects and Administration Constraints A critical pharmacodynamic interaction involves agents that affect potassium balance. Use with ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), or Potassium-Sparing Diuretics carries an officially stated risk of severe hyperkalaemia. Furthermore, combinations with other antifolate agents (e.g., Methotrexate) increase the risk of haematological toxicity. The official profile also notes that high-dose Folate supplements (5 mg daily or greater) must be restricted to prevent antagonism of the product's therapeutic anti-folate mechanism.

Borgal operates by employing a sequential double blockade to interfere with the bacterial folic acid synthesis pathway (FolA), a mechanism essential for microbial growth. This action involves Sulfadoxine competitively inhibiting the enzyme Dihydropteroate Synthase (DHPS), while Trimethoprim concurrently inhibits Dihydrofolate Reductase (DHFR). The combined action of blocking these two distinct, consecutive enzymes functions to prevent the synthesis of essential THF cofactors required for replication.

The dual mechanism exhibits pharmacodynamic synergy, where the combined effect on the FolA pathway is substantially greater than the additive effect of the individual components. This synergistic interference completely halts the subsequent synthesis of purines and thymidylate, the foundational molecular building blocks for bacterial DNA and RNA. The resulting metabolic failure produces a potent bactericidal effect, defined as the killing of microbial cells rather than mere growth inhibition. This outcome is the primary physiological consequence of the mechanism's profile.

The drug's mechanism demonstrates selective toxicity by targeting enzymes essential for bacterial folate synthesis that are absent in host cells. However, the action is functionally constrained in environments where high levels of pre-formed purines or thymidylate are available, as the bacteria can utilize these available precursors, thereby bypassing the blocked pathway.

Borgal is a fixed-combination sulfonamide antimicrobial solution formulated for parenteral administration, utilizing 200 mg/mL Sulfadoxine and 40 mg/mL Trimethoprim. Administration options include intramuscular (IM), intravenous (IV), and subcutaneous (SC) injection in cattle and pigs; however, only slow intravenous injection is used in horses.

The standardized dosing regimen is based on body weight, with the general required amount being 15 mg of total active substance per kilogram. This volume is equivalent to administering 3 mL of the injectable solution for every 50 kg of body mass. Accurate determination of body weight is necessary to ensure the correct volume is administered.

The usage schedule is set as a once-daily routine, and the course of treatment is generally for not longer than five consecutive days. Specific procedural conditions govern the administration: for IM use in cattle, the volume at a single injection site should not exceed 15 mL. Furthermore, a special instruction applies to small patients, such as piglets weighing under 4.5 kg, where the administered volume must be limited to a maximum of 0.5 mL. Adequate drinking water must be available at all times during the treatment period.

Research evidence / Overview of Studies for Borgal

The research base for Borgal, a combination of sulfadoxine and trimethoprim, primarily consists of Field Trials, Controlled Comparative Trials, and Pharmacokinetic (PK) studies across the species for which it is authorized. These studies aim to characterize the drug concentration profiles and explore parameters related to its use, with findings contributing to the broader evidence landscape.

Evidence for Systemic and Miscellaneous Bacterial Infections

The foundational evidence for the use of this antibiotic combination was established through Field Trials, which are non-randomized studies. The studies typically compared the combination to sulfadoxine used alone in the research context, and research examined clinical outcomes in these conditions. Researchers examined outcomes related to systemic or functional imbalance (e.g., overall clinical course) in study populations including cattle and pigs. What remains uncertain is that many of these foundational data points originate from older Field Trials, where the methods often lacked the randomization and blinding rigor typical of modern clinical trials.

Research in Bovine Respiratory Disease (Pneumonias)

Specific research scenarios focus on conditions associated with acute or disruptive episodes using Randomized Controlled Trial (RCT) designs, where the combination was evaluated against other contemporary antibiotic treatments. Studies monitored outcomes including treatment response rates and relapse rates. Research described patterns related to the evolution of clinical signs observed in the studies. However, some comparative studies have reported a different proportion of calves showing an initial response within the first three days of therapy when compared to newer, alternative antibiotics.

Pharmacokinetic Profile and Tissue Distribution Studies

A highly consistent and detailed body of research, utilizing Pharmacokinetic (PK) Analyses, was conducted to examine how the active ingredients are absorbed, distributed, and cleared from the body. Studies explored the drug concentration in the bloodstream (Cmax) and the time it takes for the drugs to be cleared from the body (T1/2). Reported PK data indicate that the two active ingredients have differing elimination rates from the body. This research provides context but not individual predictions of clinical success.

Durability of Effect and Long-Term Observation Periods

Across the main evidence categories, research explored short-term symptom changes, with most follow-up durations limited to the treatment period itself and a short window immediately afterward. Long-term effects are not fully established, and there is limited information for long-term outcomes regarding the sustained response or the likelihood of infection returning over intermediate or extended periods.

Key Studies & References

1. Borgal 200 mg/ml + 40 mg/ml solution for injection - Summary of Product Characteristics (HPRA)

Common questions about Borgal (FAQ)

---

Q: What is Borgal used for besides the main condition?

Official product information indicates that Borgal is used to treat a wide range of bacterial infections. This includes specific infections of the respiratory, gastro-intestinal, and urino-genital tracts. It is also indicated for conditions like mastitis and infectious lesions of the skin in the target animal species.

---

Q: Is Borgal the same type of medicine as other common treatments for this condition?

Borgal is a type of medicine known as a potentiated sulfonamide antibiotic. It is composed of two active ingredients, sulfadoxine and trimethoprim, that work together. This combination achieves a sequential double blockade of bacterial metabolism, which is a specific mechanism that defines this class of medication.

---

Q: How quickly does Borgal start working?

According to the official pharmacokinetic data, the active substances in Borgal are absorbed relatively quickly after injection. Maximal levels of both active components in the blood plasma are generally reached within 1 to 8 hours.

---

Q: Does Borgal cause weight gain or weight loss?

Official product information for Borgal does not list weight changes as a common adverse reaction. Regulatory reviews of the active ingredients have mentioned potential links to reduced weight gain in specific toxicology studies, although this is not listed as a common reaction in the product's official label.

---

Q: Are there any major diet changes required while taking Borgal?

Official instructions highlight one key requirement: adequate drinking water must be available at all times throughout the treatment period. This measure is essential throughout the treatment period to help support the animal’s kidney function.

---

Q: Is it common to feel tired when starting Borgal?

Tiredness or fatigue is not listed as a common side effect in the official product information for Borgal. However, general regulatory data for medicines containing these active ingredients have documented drowsiness or lethargy as an uncommon or very rare side effect.

---

Q: Can Borgal affect sleep patterns?

The official product information does not list direct effects on sleep. However, the active ingredients in Borgal have been associated with very rare psychiatric effects, including insomnia (difficulty sleeping) and nightmares.

---

Q: Is Borgal safe to take with blood pressure medications?

Official warnings document a potential interaction risk with certain types of blood pressure medications, including ACE Inhibitors, ARBs, or Potassium-Sparing Diuretics, due to a stated risk of hyperkalaemia (high potassium levels). Consult the official product information for a full list of known interactions.

---

Q: What are the most common side effects of Borgal mentioned by patients?

Official product documents for Borgal list adverse effects such as hypersensitivity reactions and acute shock. However, the frequency of most of the specific adverse effects is officially classified as undetermined, meaning it cannot be reliably estimated from the available data.

---

Q: Does Borgal require any special monitoring or blood tests?

The medicine is contraindicated in patients with pre-existing blood disorders (blood dyscrasias). Due to the potential risk to the blood system, close professional supervision may be required for high-risk patients, such as those with pre-existing blood disorders.

---

Q: What happens if I take more Borgal than is described on the label?

The official product information for Borgal states that there are 'No specific overdose reactions known' for this specific formulation. Acute and chronic toxicity, however, are generally discussed for the active ingredients in regulatory documents.

---

Q: Is Borgal a narcotic or controlled substance?

Borgal is classified by regulatory authorities as a potentiated sulfonamide antibiotic. It is not listed as a narcotic or controlled substance.

---

Q: What are some less common but serious side effects of Borgal?

Official warnings document serious risks associated with this medicine. These include hypersensitivity reactions, potential damage to the liver (Hepato-biliary), kidney (Renal and Urinary), and blood (Blood and Lymphatic) systems, and acute events like cardiac and respiratory shock.

---

Q: Can Borgal cause changes in mood or personality?

The product information itself does not list changes in mood or personality. However, the active ingredients in Borgal have been associated with very rare psychiatric effects, including depression, hallucinations, and confusional states.

---

Q: Is it true Borgal has a risk of [Specific Rare Side Effect]?

Official regulatory documents confirm that this drug carries the potential risk for severe adverse effects. These include hypersensitivity, anaphylactic reactions, and risks to major organ systems like the liver, kidney, and blood systems.

---

Q: When should I contact a healthcare professional about Borgal side effects?

The product information states that if signs of severe reactions, such as intolerance or shock, are observed, the administration of the medicine should be interrupted immediately. In such cases, immediate professional consultation may be necessary to address the reaction.

---

Q: Is Borgal available over the counter?

No. Borgal is a medically important antimicrobial and is officially designated by regulatory bodies as a Prescription Only (Rx) medicine.

---

Q: How is Borgal eliminated from the body?

The active components of Borgal are cleared from the body primarily through excretion in the urine. One of the active components is also partially excreted via faeces, and both components undergo metabolism before elimination.

---

Q: Can Borgal affect my cholesterol levels?

The product information does not list changes in cholesterol as an adverse reaction of this medicine. However, toxicology studies with high doses of the active ingredients have shown increased serum cholesterol concentrations in some animals.

---

Q: How does Borgal compare to a placebo in studies?

The clinical research evidence provided in the official product monograph focuses on comparisons to the use of sulfadoxine used alone or against other existing antibiotic treatments, rather than against an inactive placebo.

Storage Conditions and Stability

The official labeled requirements for Borgal (Sulfadoxine/Trimethoprim injectable solution) specify that it must be stored at room temperature, below 25 C.

The product must be protected from physical and environmental damage: it is explicitly required to Do not freeze the solution, and it should be stored in a dry place, within its original container or carton to protect it from light.

Regarding stability, the shelf life of the unopened product is 5 years. Once the container is first opened, the in-use shelf life is limited to 6 weeks.

Disposal and Child Safety

As a safety precaution, the medicine must be kept out of the sight and reach of children.

Disposal of unused or expired product and its waste must follow local regulatory requirements. The official labeling mandates that the product and its container must not be discharged into drains, water courses, or onto the ground.